Lv6
1668 积分 2024-06-30 加入
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
18天前
已完结
Contemporary approach to the diagnosis and classification of intestinal T-cell lymphomas
1个月前
已完结
The Treatment of Marginal Zone Lymphoma
2个月前
已完结
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML
2个月前
已完结
Dismantling relapsed/refractory mantle cell lymphoma
7个月前
已完结
Treatment of relapsed/refractory MCL
7个月前
已完结
Frontline management of mantle cell lymphoma
7个月前
已完结
Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study
7个月前
已完结
皖公网安备34019202002308
